HealthCap is happy to welcome Mr. Andrew Kay as a Senior Advisor. Mr. Kay brings more than 30 years of commercial and leadership experience in the pharmaceutical sector, latest as CEO of HealthCap company Algeta ASA. During Mr. Kay’s leadership, Algeta’s lead product, Xofigo, was approved by the FDA and EMA for the treatment of bone metastases in castration resistant prostate cancer patients, followed by a strong commercial launch. In February 2014, Algeta was acquired by its partner Bayer AG for USD 2.9 billion. Mr. Kay’s previous assignments include Executive Director, Commercial, at HealthCap company Renovo, Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots.